Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Recommended
Do these things indoors and out to keep your home cool in summer heat
Recommended
5 On Your Side shares 7 simple ways to cut down your energy bill this summer
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Allakos Inc
(NQ:
ALLK
)
1.120
-0.050 (-4.27%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Allakos Inc
Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria
May 28, 2024
From
Allakos Inc.
Via
GlobeNewswire
Allakos Provides Business Update and Reports First Quarter 2024 Financial Results
May 09, 2024
From
Allakos Inc.
Via
GlobeNewswire
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
March 14, 2024
From
Allakos Inc.
Via
GlobeNewswire
Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024
February 26, 2024
From
Allakos Inc.
Via
GlobeNewswire
Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition
February 12, 2024
From
Allakos Inc.
Via
GlobeNewswire
Allakos Announces a Restructuring to Focus on Development of AK006
January 16, 2024
From
Allakos Inc.
Via
GlobeNewswire
Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints
January 16, 2024
From
Allakos Inc.
Via
GlobeNewswire
Allakos Provides Business Update and Reports Third Quarter 2023 Financial Results
November 13, 2023
From
Allakos Inc.
Via
GlobeNewswire
Allakos Appoints Neil Graham to its Board of Directors
August 30, 2023
From
Allakos Inc.
Via
GlobeNewswire
Allakos Provides Business Update and Reports Second Quarter 2023 Financial Results
August 09, 2023
From
Allakos Inc.
Via
GlobeNewswire
Allakos Appoints Rand Sutherland and Dolca Thomas to its Board of Directors
August 02, 2023
From
Allakos Inc.
Via
GlobeNewswire
Allakos Presents Preclinical Data at EAACI Hybrid Congress 2023 Highlighting Lirentelimab and AK006 Mechanisms of Mast Cell Inhibition
June 12, 2023
From
Allakos Inc.
Via
GlobeNewswire
Allakos Announces Upcoming Presentation on Lirentelimab and AK006 Mast Cell Inhibition at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2023
June 05, 2023
From
Allakos Inc.
Via
GlobeNewswire
Allakos Provides Business Update and Reports First Quarter 2023 Financial Results
May 09, 2023
From
Allakos Inc.
Via
GlobeNewswire
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
March 06, 2023
From
Allakos Inc.
Via
GlobeNewswire
Allakos Announces Publication of AK006 Mechanism of Action Manuscript in Communications Biology
November 29, 2022
From
Allakos Inc.
Via
GlobeNewswire
Allakos Presents Preclinical Data on AK007, a Siglec-10 Antagonist Antibody, at the Society for Immunotherapy of Cancer’s 37th Annual Meeting
November 10, 2022
From
Allakos Inc.
Via
GlobeNewswire
Allakos Provides Business Update and Reports Third Quarter 2022 Financial Results
November 07, 2022
From
Allakos Inc.
Via
GlobeNewswire
INVESTIGATION REMINDER: The Schall Law Firm Announces Investigation of Breaches of Fiduciary Duties by Management of Allakos Inc.– ALLK
June 10, 2022
From
The Schall Law Firm
Via
Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces Investigation of Breaches of Fiduciary Duties by Management of Allakos Inc.– ALLK
June 09, 2022
From
The Schall Law Firm
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.